000			03284cam a2200397Ii 4500
001			94866
003			ES-MaUEC
005			20230102112635.0
006			m o d
007			cr cnu---unuuu
008			161116s2017 sz ob 000 0 eng d
020			_a3319460072 _q(electronic bk.)
020			_a9783319460079 _q(electronic bk.)
020			_z3319460056
020			_z9783319460055 _q(print)
035			_a(OCoLC)962750908 _z(OCoLC)962795411 _z(OCoLC)965707391 _z(OCoLC)966567309 _z(OCoLC)974651499 _z(OCoLC)981101617 _z(OCoLC)1005820808
040			_aN$T _cN$T _dIDEBK _dEBLCP _dGW5XE _dN$T _dYDX _dOCLCF _dAZU _dUAB _dCOO _dUPM _dIOG _dVT2 _dESU _dJBG _dIAD _dICW _dICN _dIAD _dOTZ _dMERER _dOCLCQ _dU3W _dMERUC _dES-MaUEC _bspa
050		4	_aRC591 _b2017 EB
100	1		_aPelaia, Girolamo, _eautor
245	1	0	_aAsthma : _btargeted biological therapies _cGirolamo Pelaia, Alessandro Vatrella, Rosario Maselli.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
504			_aIncluye referencias bibliográficas
505	0		_aIntroduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.
520	3		_aThis book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.
650		7	_aAsma _2embne _0(OCoLC)fst00819329 _0 _9140908
700	1		_aMaselli, Rosario, _eautor
700	1		_aVatrella, A. _q(Alessandro), _eautor
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-46007-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c94866 _d94866 _x1